In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on Rezolute, with a price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yun Zhong has given his Buy rating due to a combination of factors related to Rezolute’s progress in developing its treatment for congenital hyperinsulinism (cHI) and tumor-induced hyperinsulinism (tHI). The company has made significant strides with its Phase 3 sunRIZE study, showing promising efficacy in treating cHI, especially in younger patients who carry specific genetic mutations. This positions the treatment, ersodetug, to potentially outperform the standard of care, particularly given its Breakthrough Therapy designation, which could expedite its review process.
Furthermore, Rezolute’s financial health appears strong, with a substantial cash reserve following a successful public offering, providing a runway through mid-2027. The recent hiring of a Chief Commercial Officer indicates that commercialization strategies are already being planned, aligning with the projected U.S. market entry in 2027. These factors, combined with the ongoing Phase 3 study for tHI and the FDA’s alignment on study design, bolster confidence in Rezolute’s potential for future success, justifying the Buy rating.
Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Protagonist Therapeutics, and Rocket Pharmaceuticals. According to TipRanks, Zhong has an average return of -11.4% and a 42.73% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.